Latest Period
n/a
Security Snapshot
Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) Institutional Ownership
CUSIP: 984241109
13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025
Institutions Reporting
Shares (Excl. Options)
Price
$8.61
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- YMAB
- Shares outstanding
- 45,101,565
- Price per share
- $8.61
- Price from insider filings
- $8.61
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- YMAB - Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 984241109.
- Latest finished 13F holder period is not available.
- 1 significant owner is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 2 to 0 between Q3 2025 and Q4 2025.
- Reported value moved from $78,346 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
984241109
Latest holder period
n/a
13F holders
13D/G owners
1
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 984241109:
Significant Owners of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ACORN BIOVENTURES, L.P. | 6.2% | -11% | $13,338,337 | -$1,431,000 | 2,796,297 | -9.7% | Anders Hove | 19 Aug 2025 |
Institutional Holders of Y-mAbs Therapeutics, Inc. - Common Stock, $0.0001 par value per share (YMAB) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$78,346 | $8.61 | 0 |
| 2025 Q3 | 16,393 | $78,346 | -$125,346,804 | $6.66 | 2 |
| 2025 Q2 | 27,903,915 | $125,848,990 | -$3,989,579 | $4.51 | 96 |
| 2025 Q1 | 28,806,277 | $127,612,664 | -$6,925,835 | $4.43 | 102 |
| 2024 Q4 | 28,798,220 | $225,491,854 | -$942,932 | $7.83 | 111 |
| 2024 Q3 | 25,737,929 | $338,544,539 | +$17,304,991 | $13.15 | 105 |
| 2024 Q2 | 24,348,906 | $294,136,627 | +$14,837,664 | $12.08 | 95 |
| 2024 Q1 | 22,993,565 | $373,875,065 | +$49,054,572 | $16.26 | 94 |
| 2023 Q4 | 20,232,989 | $137,987,136 | +$5,157,820 | $6.82 | 93 |
| 2023 Q3 | 19,680,958 | $107,258,625 | +$812,221 | $5.45 | 98 |
| 2023 Q2 | 19,501,430 | $132,412,962 | +$4,779,033 | $6.79 | 94 |
| 2023 Q1 | 19,046,672 | $95,423,185 | -$1,127,392 | $5.01 | 84 |
| 2022 Q4 | 19,342,439 | $94,388,828 | -$55,189,832 | $4.88 | 90 |
| 2022 Q3 | 23,585,540 | $340,103,128 | -$17,897,969 | $14.42 | 95 |
| 2022 Q2 | 24,763,276 | $374,657,143 | -$7,577,417 | $15.13 | 90 |
| 2022 Q1 | 25,303,485 | $300,604,312 | -$14,876,098 | $11.88 | 87 |
| 2021 Q4 | 25,735,284 | $417,099,601 | -$24,204,070 | $16.21 | 94 |
| 2021 Q3 | 26,245,129 | $749,015,343 | -$2,981,846 | $28.54 | 96 |
| 2021 Q2 | 26,145,321 | $886,898,417 | -$1,159,329 | $33.80 | 99 |
| 2021 Q1 | 26,332,523 | $796,209,961 | +$116,007,549 | $30.24 | 116 |
| 2020 Q4 | 22,809,127 | $1,129,308,254 | +$38,442,838 | $49.51 | 115 |
| 2020 Q3 | 21,437,747 | $823,089,252 | +$3,018,102 | $38.39 | 105 |
| 2020 Q2 | 21,284,113 | $919,504,408 | +$53,403,136 | $43.20 | 108 |
| 2020 Q1 | 20,069,737 | $522,452,562 | +$16,002,866 | $26.10 | 80 |
| 2019 Q4 | 19,404,437 | $606,386,157 | +$184,880,658 | $31.25 | 81 |
| 2019 Q3 | 13,139,685 | $342,418,499 | +$56,540,594 | $26.06 | 65 |
| 2019 Q2 | 10,972,436 | $250,918,214 | +$54,344,617 | $22.87 | 59 |
| 2019 Q1 | 8,480,229 | $222,267,926 | -$3,116,524 | $26.21 | 44 |
| 2018 Q4 | 8,686,033 | $175,686,000 | +$16,927,076 | $20.34 | 42 |
| 2018 Q3 | 7,733,371 | $205,387,000 | +$205,387,000 | $26.56 | 38 |